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Drug summary box  
Drug name Hydrocortisone  
 
Phase IV  
 
Indication Replacement therapy of adrenal insufficiency in infants, children and 
adolescents (from birth to < 18 years old).   
Pharmacology description/mechanism of action  
Synthetic form of naturally occurring glucocorticoid hormone cortisol.  Pleotropic effects 
through activation of the glucocorticoid receptor in multiple tissues. 
 
Route of administration Oral 
 
Pivotal trial(s) Infacort 003 Single arm pharmacokinetic study of drug in children aged 
from birth to 6 years with adrenal insufficiency.  To our knowledge first published 
interventional pharmacokinetic study in this age and patient group. 
 
  
 
 
Background and overview of the market: 
The 2017 European commission report on paediatric medicines stated: ³there is a broad 
consensus that children deserve access to medicines that have been specifically developed 
and researched for their use "; and "crushing adult tablets and using only a portion...comes 
with the risk of inefficacy and/or adverse reactions in children" (1).  Despite this guidance, 
children with adrenal insufficiency in Europe still receive crushed adult tablets or 
individually compounded preparations of hydrocortisone. Adrenal insufficiency results from 
failure to synthesise adequate levels of the stress hormone cortisol from the adrenal gland and 
is either primary due to failure of the adrenal gland or secondary due to failure of the 
pituitary; in children the commonest cause is Congenital Adrenal Hyperplasia (CAH)(2).  
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Patients with adrenal insufficiency will die from an adrenal crisis unless cortisol is replaced 
and children with CAH have the additional problem that the compensatory pituitary drive to 
the adrenal results in excess adrenal androgen secretion leading to pseudo-precocious puberty 
and virilisation in both male and female children.  Until the 1950s patients with adrenal 
insufficiency inevitably died through adrenal crisis, and the discovery and introduction of 
glucocorticoid therapy was life-saving.  However, treatment maybe complicated by excess 
glucocorticoid replacement which puts children at risk of poor growth, osteoporosis later in 
life, obesity, hypertension, depression and increased risk of cardiovascular disease (3).  
Guidance for use of replacement glucocorticoids in children is to use the lowest possible 
dose, and to use the native hormone, hydrocortisone (cortisol), rather than synthetic steroids 
such as prednisolone and dexamethasone which have a greater suppressive effect on growth 
(4).  The challenge for paediatric patients and their health care providers is that 
hydrocortisone is only licensed in 10 and 20mg tablet doses in the European Union and 
children require much smaller doses (of the order of 1-2mg three times daily in infants), and 
are unable to swallow tablets designed for adults (5). Current clinical practice is for 
pharmacists to compound hydrocortisone either by tablet crushing or using hydrocortisone 
base to produce a powder or special solutions of hydrocortisone or in some countries, such as 
the United Kingdom, for parents to crush tablets (6-8). All such practice is unlicensed and not 
subject to the level of regulation and quality control of licensed drug manufacture where  
Good Manufacturing Practice (GMP) regulations mean that every aspect of manufacturing 
must be described, controlled and regularly assessed with a quality management system in 
place at each step. This means for instance that the  active ingredient in a product should be 
controlled within strict parameters, usually 95-105% of the label claim (9).   By contrast the 
production of compounded medicine is much less regulated and not subject to GMP, resulting 
in the Food and Drug Administration (FDA) warning that;  ³)'$GRHVQRWYHULI\WKe safety, 
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RUHIIHFWLYHQHVVRIFRPSRXQGHGGUXJV´ (9). A recent study, reported that 21.4% of 
pharmacist-compounded hydrocortisone batches failed to meet European pharmacopeia 
guidelines and a further 3.6% of batches contained no hydrocortisone (7).  When parents 
rather than pharmacists crush  hydrocortisone tablets the results are worse: data from a UK 
study of parents of children with adrenal insufficiency showed that >50% of doses were at 
least 10% out of specification (8).   Parents find crushing tablets difficult: 27% report not 
having been instructed in how to prepare doses, and for those that did have instruction, only 
10% reported having repeat training.  Moreover, changes in manufacturing of hydrocortisone 
products can lead to difficulties with crushing or splitting tablets (10).  The inconsistency in 
hydrocortisone dose created by compounding can lead to severe clinical consequences with 
poor disease control due to undertreatment (7) and Cushings syndrome due to overtreatment 
(11,12).  Hydrocortisone is bitter and sucrose or lactose are often added to compounded 
tablets to improve palatability, however this has adverse effects on dental health and in 
children with lactose deficiency (13). EMA guidance for developing new medicines for 
children advises against sweeteners of all forms (14). Thus, there is a need for a licensed 
paediatric appropriate formulation of hydrocortisone. 
 
Infacort Programme- development of a paediatric appropriate immediate-release 
granule formulation of hydrocortisone: 
Alkindi® (Diurnal Ltd.) is a formulation of hydrocortisone developed under an EU-FP7 
grant, The TAIN (Treatment of Adrenal Insufficiency in Neonates) Project, to meet the needs 
of paediatric adrenal insufficiency patients.  Alkindi® is a multiparticulate granule 
formulation with maximum granule diameter controlled by passing through a 0.8mm sieve 
i.e. well below the FDA Guidance to industry on sprinkle formulation limits of 2.5mm 
diameter, and allows for swallowing of granules even by neonates (15).  The granules are 
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presented within a transparent capsule that is opened for dosing, this allows for accurate 
paediatric dosing with dose strengths of 0.5, 1.0, 2.0, and 5.0 mg (Figure 1).  The granules are 
so small that even the 0.5 mg capsule contains ~900 granules. Each granule has an inert 
cellulose core, a spray coat of hydrocortisone and a taste masking layer to prevent the bitter 
taste of hydrocortisone being experienced by the patient. 
 
Hydrocortisone has been in use as a human medicine for over 60 years and is the 
pharmaceutical form of the natural glucocorticoid hormone cortisol. Cortisol binds the 
cytosolic glucocorticoid receptor which, translocates to the cell nucleus, and regulates gene 
expression through either transactivation or transrepression.  Glucocorticoids also mediate 
actions through non-genomic mechanisms (16). Hydrocortisone is rapidly absorbed from the 
gut with almost 100% bioavailability reaching peak concentrations around an hour after being 
taken fasted (17) .  Circulating hydrocortisone is approximately 90% protein bound mostly by 
cortisol binding globulin, but also by albumin.  The binding proteins are saturable leading to 
non-linear pharmacokinetics whereby higher doses of hydrocortisone are cleared quicker 
(17,18). Hydrocortisone is metabolised by 11b-Hydroxysteroid dehydrogenase type 2 (11b-
HSD2) to inactive cortisone in the kidney and other tissues and the reverse conversion occurs 
in liver and adipose tissue due to 11b-HSD1.  Both cortisol and cortisone are renally excreted 
and hydrocortisone can be sequentially metabolised to allo-tetrahydrocortisol, 
tetrahydrocortisol and tetrahydrocortisone, also renally excreted (19).  
 
Safety data gathered from pharmacovigilance of glucocorticoids generally reflects the 
widespread use of steroids as anti-inflammatory agents and  not the rare condition of adrenal 
insufficiency. Anti-inflammatory doses of steroids are frequently ten-fold those used in 
replacement therapy and as most adverse effects are dose related these are less relevant when 
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prescribing hydrocortisone for adrenal replacement therapy.   However, psychiatric adverse 
effects have been described in patients treated for adrenal insufficiency (20).  Drug-drug 
interactions are seen in patients with adrenal insufficiency: potent CYP3A4 inducers such as 
anti-convulsants increase the clearance of steroids and require dose adjustment of 
hydrocortisone upwards, whereas enzyme inhibitors such as azole anti-fungals and 
erythromycin increase cortisol concentrations requiring a reduction in hydrocortisone dose 
(21-23).   
 
Clinical studies with Alkindi®: 
Development of Alkindi® was under a Paediatric Investigation Plan (EMEA-001283-PIP0-
12) to support a hybrid marketing authorisation application for a Paediatric Use Marketing 
Authorisation (PUMA).  The plan allowed for demonstration of bioequivalence to a marketed 
hydrocortisone (Auden Mckenzie Hydrocortisone 10mg) at phase 1 followed by a phase 3 
study demonstrating appropriate exposure in paediatric adrenal insufficiency patients. To 
demonstrate bioequivalence between Alkindi® and the reference hydrocortisone product 
healthy adult male volunteers were treated with dexamethasone to suppress their 
hypophyseal-pituitary-adrenal axes.  The study was a single centre, open label, randomised, 
crossover study in 16 dexamethasone-suppressed healthy adult male volunteers which 
compared the pharmacokinetics of Alkindi® with the reference hydrocortisone tablets at a 
single dose of 10mg and also evaluated the dose proportionality of Alkindi® at doses of 0.5, 
2.0, 5.0 and 10 mg.   The study demonstrated bioequivalence of Alkindi® to immediate 
release hydrocortisone (Figure 2)(5).  
 
The phase 3 study was undertaken in the Charite hospital in Berlin (6).  The study was a 
sequential age cohort design to maximise subject safety.  Initially 12 patients with adrenal 
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insufficiency aged 2 years to 6 years were studied. Following analysis of safety outcomes, a 
further 6 infants with adrenal insufficiency aged 1 month to 2 years were studied, and finally 
6 neonates aged less than 28 days with adrenal insufficiency were studied.  The protocol was 
similar in all cohorts with patients receiving a morning dose of Alkindi® identical to their 
usual morning dose of compounded hydrocortisone.  Dosing was at least 8 hours after the 
SDWLHQWV¶SUHYLRXVGRVHRIK\GURFRUWLVRQHDQGZDVDWOHDVWKRXUVDIWHUIRRGLQFKLOGUHQDJHG
twelve months or more, and 45 minutes after food in those aged less than 12 months.  
Following dosing the children had blood sampling at 0, 60 and 240 minutes with the primary 
endpoint being maximum serum cortisol concentration up to 240 minutes after Alkindi® 
administration as measured by liquid chromatography-mass spectrometry.  Secondary 
endpoints included palatability of Alkindi® (for which new 5 point Likert questionnaires 
were developed for parents and patients), adverse events and vital signs recorded during the 
study.   23 of the 24 children studied had Congenital Adrenal Hyperplasia and one patient had 
hypopituitarism, the median age was 3 years and 3 months, 54.2% were male and all subjects 
were white.  All children were successfully dosed with a median dose of 2mg.  In all children 
cortisol increased from baseline to a Cmax at 60 minutes (Figure 3). The absolute geometric ± 
SD (standard deviation) mean cortisol concentration at Cmax was 575.8 ± 299.5 nmol/L for 
the overall population (> 2years cohort: 547.1 ± 82.9 nmol/L; 1 month to 2 years cohort: 
450.1 ± 88.9 nmol/L; < 28 days cohort: 815.7 ± 474.9 nmol/L). The rapid absorption and 
clearance of cortisol was similar to findings in previous studies of children dosed with 
immediate release hydrocortisone (24).  The hydrocortisone Cmax was similar to peak 
concentrations of cortisol in children with intact hypophyseal-pituitary-adrenal axes (25).   
Alkindi® was generally well received by parents and children alike.  82.6% of parents 
agreed/strongly agreed that their child found swallowing Alkindi® easy and 95.5% said that 
they would prefer Alkindi® IRUWKHLUFKLOG¶VWUHDWPHQWRYHUWKHLUXVXDOK\GURFRUWLVRQH
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formulation. Six of the 12 children in the oldest cohort responded to an adjusted palatability 
TXHVWLRQQDLUHZLWKVXEMHFWVUHSRUWLQJWKDWWKHWDVWHIHHOLQPRXWKDQGHDVHRI
swallowing were very good and that they were likely to take the medicine again. No serious 
adverse events were seen throughout the study, and the adverse events seen were mild (most 
common reported were diarrhoea, vomiting and rash) and not attributed to investigational 
product (6). 
 
Following the phase 3 Alkindi® study subjects could choose to continue in a safety extension 
study.  18 subjects elected to continue, and at time of writing 12 patients remain on treatment. 
Drop outs from the study related to problems with dosing of the older children who were used 
to taking a sweetened compounded hydrocortisone liquid in the evening. These subjects were 
aged between 2-6 years and the investigators felt treatment refusal was related to age 
appropriate behavioural development rather than rejection of the specific therapy. Following 
a change of advice to allow sprinkling of granules on yoghurt or fruit mousse there have been 
no further drop outs.  Indeed, one patient who initially refused Alkindi® then demanded to go 
back on Alkindi®.   At one year, patients on Alkindi® had good disease control, no abnormal 
progression in pubertal status and growth was as expected.  
 
Current status of Alkindi®: 
Alkindi® received a centralised paediatric use marketing authorisation in the European Union 
on 9th February 2018 for replacement therapy of adrenal insufficiency in infants, children and 
adolescents (from birth to < 18 years old)(Reference Alkinid SmPC Diurnal Ltd.).  Alkindi® 
is also being investigated under an Investigational New Drug programme in the United States 
of America.   
 
9 
 
Conclusions: 
Alkindi® is a novel paediatric formulation of immediate release hydrocortisone  licensed for 
use in paediatric adrenal insufficiency with doses of 0.5, 1.0, 2.0 and 5.0 mg (reference 
Alkindi SmPC Diurnal Ltd).  Alkindi® provides a consistent licenced treatment option for 
accurate dosing in children with adrenal insufficiency where compounded adult tablets of 
hydrocortisone are unsuitable. 
 
Expert commentary:  
Adrenal insufficiency was inevitably fatal before the introduction of glucocorticoid 
replacement therapy in the 1950s. Hydrocortisone replacement therapy is life-saving, 
however there has been little innovation since its introduction in the 1960s and there is 
increasing recognition that both children and adults with adrenal insufficiency have an 
increased morbidity and mortality related to under or over treatment with glucocorticoid (3).   
Treatment of paediatric patients with adrenal insufficiency is challenging due to the lack of 
appropriate glucocorticoid preparations for children and the use of either pharmacy- or 
parent-compounded hydrocortisone tablets.  Paediatric patients suffer from over- and under-
treatment (7), growth outcomes in congenital adrenal hyperplasia are suboptimal (26), and for 
parents there is the continuous stress of managing a child at risk of adrenal crisis LIWKH\GRQ¶W
receive the correct medication and this is most stressful in the youngest children (27).  
Compounding hydrocortisone has multiple issues beyond inconsistent dosing including the 
practical problems for parents who compound the drug themselves or travel long distances to 
a compounding pharmacy and the cost of compounding by the pharmacy.   Alkindi® is a 
licenced formulation providing accurate dosing and allows paediatricians to titrate doses to 
the needs of the growing child. The Alkindi® formulation is easily administered to young 
children or older children who find taking tablets difficult.  
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Five-year view:  
In 2017 the European Commission reported on the status of paediatric medicines ten years 
after the introduction of paediatric medicines legislation (1).  Although there had been an 
increase in the number of successfully completed paediatric investigation plans this was 
mainly in areas where the needs of paediatric and adult patients overlapped, and progress in 
rare childhood disease areas has been slow.  The commission is investigating how to improve 
this situation, and it seems likely that there will be increasing provision of medicines for 
children.  In adrenal insufficiency the development of Alkindi® is an important first step in 
improving the care of children with adrenal insufficiency and its PUMA is only the fourth 
approved PUMA under this route. However, replacing the natural circadian rhythm of 
cortisol is not addressed by Alkindi® (28). A modified release formulation of hydrocortisone 
is under development for CAH by Diurnal Ltd that more closely mimics the overnight 
physiological pattern of cortisol release and in a phase 2 study improved biochemical control 
in patients with CAH (29,30). It is anticipated that this product will be developed for 
children.  Finally, a number of non-glucocorticoid products are under development that may 
address the excess of androgens in CAH (31).  These are in early stage trials, but may 
improve control and reduce steroid requirements in patients with CAH. 
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Key issues:  
x Currently children with adrenal insufficiency are dependent on compounded 
hydrocortisone formulations which do not provide accurate dosing, are bitter to taste 
and associated with poor disease control resulting in under and over treatment, 
adrenal crises and poor growth. 
x Alkindi®, is an immediate release hydrocortisone formulation with taste masking, 
licenced under a PUMA, and provides an easy to administer, well tolerated, paediatric 
formulation which allows accurate dose titration in neonates, infants and children. 
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Figures: 
Figure 1: Alkindi® is a granule formulation of immediate release hydrocortisone that can be 
dosed in neonates. Figure shows that by combining capsules incremental doses can be used as 
the child grows. (Source Diurnal Ltd.) 
  
Empty first capsule (2mg) onto spoon  Empty second capsule (0.5mg) onto spoon  
Give complete dose (2.5mg) to child following 
administration instructions 
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Figure 2: Alkindi® was bioequivalent to hydrocortisone tablets in adult phase 1 trials. Figure 
shows Alkindi® at doses 0.5 to 10mg compared to a standard 10mg hydrocortisone tablet. 
(Whitaker et al. JCEM 2015) 
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Figure 3: Geometric mean ±SEM cortisol levels following single dose of Alkindi® in 
neonates, infants and children <6 years. (Data from Infacort003 study Diurnal Ltd.) 
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